Proteomic Changes in Cerebrospinal Fluid of Presymptomatic and Affected Persons Carrying Familial Alzheimer Disease Mutations
Open accessAbstract
OBJECTIVE: To identify cerebrospinal fluid (CSF) protein changes in persons who will develop familial Alzheimer disease (FAD) due to PSEN1 and APP mutations, using unbiased proteomics. DESIGN: We compared proteomic profiles of CSF from individuals with FAD who were mutation carriers (MCs) and related noncarriers (NCs). Abundant proteins were depleted and samples were analyzed using liquid chromatography-electrospray ionization-mass spectrometry on a high-resolution time-of-flight instrument. Tryptic peptides were identified by tandem mass spectrometry. Proteins differing in concentration between the MCs and NCs were identified. SETTING: A tertiary dementia referral center and a proteomic biomarker discovery laboratory. PARTICIPANTS: Fourteen FAD MCs (mean age, 34.2 years; 10 are asymptomatic, 12 have presenilin-1 [PSEN1 ] gene mutations, and 2 have amyloid precursor protein [APP ] gene mutations) and 5 related NCs (mean age, 37.6 years). RESULTS: Fifty-six proteins were identified, represented by multiple tryptic peptides showing significant differences between MCs and NCs (46 upregulated and 10 downregulated); 40 of these proteins differed when the analysis was restricted to asymptomatic individuals. Fourteen proteins have been reported in prior proteomic studies in late-onset AD, including amyloid precursor protein, transferrin, α(1)β-glycoprotein, complement components, afamin precursor, spondin 1, plasminogen, hemopexin, and neuronal pentraxin receptor. Many other proteins were unique to our study, including calsyntenin 3, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 4 glutamate receptor, CD99 antigen, di- N-acetyl-chitobiase, and secreted phosphoprotein 1. CONCLUSIONS: We found much overlap in CSF protein changes between individuals with presymptomatic and symptomatic FAD and those with late-onset AD. Our results are consistent with inflammation and synaptic loss early in FAD and suggest new presymptomatic biomarkers of potential usefulness in drug development.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Synaptic changes occurring even a decade before clinical onset reflect the potential applicability of synaptic proteins as therapeutic targets.
“The synaptic changes occurring even a decade before clinical onset reflect the potential applicability of synaptic proteins as therapeutic targets (Ringman et al. 2012).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Ringman et al. 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641 · see citing works
Abdi, F. A., Quinn, J. F., Jankovic, J. J., McIntosh, M. W., Leverenz, J. B., Peskind, E. R., Nixon, R., Nutt, J. G., Chung, K., Zabetian, C. P., et al. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9309 · Cited by 385 · see citing works
A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease
Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G. L., Burkhard, P. R., Hochstrasser, D. F., & Sanchez, J. (2003) · PROTEOMICS · doi:10.1002/pmic.200300470 · Cited by 375 · see citing works
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
Puchades, M. A., Hansson, S., Nilsson, C. L., Andreasen, N., Blennow, K., & Davidsson, P. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.08.005 · Cited by 306 · see citing works
Heme scavenging and the other facets of hemopexin
Tolosano, E., Fagoonee, S., Morello, N., Vinchi, F., & Fiorito, V. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2787 · Cited by 272 · see citing works
CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases
Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J. J., Kenney, C., Chung, K. A., Millard, S. P., Nutt, J. G., & Montine, T. J. (2008) · American Journal of Clinical Pathology · doi:10.1309/w01y0b808emeh12l · Cited by 263 · see citing works
Bern, M. W., Cai, Y., & Goldberg, D. T. (2007) · Analytical Chemistry · doi:10.1021/ac0617013 · Cited by 207 · see citing works
Sia, G.-M., Béïque, J.-C., Rumbaugh, G., Cho, R., Worley, P. F., & Huganir, R. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.020 · Cited by 201 · see citing works
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198 · see citing works
Self-citationNovel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment
Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., Pickering, E. H., Kühn, M., Chen, Y., McCluskey, L. F., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0667-0 · Cited by 196 · see citing works
Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease
Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. R., & Lee, K. H. (2006) · Annals of Neurology · doi:10.1002/ana.21038 · Cited by 185 · see citing works
Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid
Zhang, J., Goodlett, D. R., Peskind, E. R., Quinn, J. F., Zhou, Y. F., Wang, Q., Pan, C., Yi, E. C., Eng, J. K., Aebersold, R. H., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.012 · Cited by 167 · see citing works
Yin, G. N., Lee, H. W., Cho, J.-Y., & Suk, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.058 · Cited by 143 · see citing works
Wirths, O., Breyhan, H., Marcello, A., Côtel, M.-C., Brück, W., & Bayer, T. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.011 · Cited by 134 · see citing works
Comi, C., Carecchio, M., Chiocchetti, A., Nicola, S., Galimberti, D., Fenoglio, C., Cappellano, G., Monaco, F., Scarpini, E., & Dianzani, U. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1309 · Cited by 120 · see citing works
Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O., & Tabaton, M. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.01.021 · Cited by 117 · see citing works
Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease
Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J. R., & Beach, T. G. (2009) · Biomarkers · doi:10.3109/13547500903108423 · Cited by 108 · see citing works
Portelius, E., Andréasson, U., Ringman, J. M., Büerger, K., Daborg, J., Buchhave, P., Hansson, O., Harmsen, A., Gustavsson, M. K., Hanse, E., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-2 · Cited by 94 · see citing works
Self-citationFox, N. (1997) · Brain · doi:10.1093/brain/120.3.491 · Cited by 93 · see citing works
Murrell, J. R., Ghetti, B. F., Cochran, E. J., Macías-Islas, M. Á., Medina, L. D., Varpetian, A., Cummings, J. L., Mendez, M. F., Kawas, C. H., Chui, H. C., et al. (2006) · Neurogenetics · doi:10.1007/s10048-006-0053-1 · Cited by 75 · see citing works
Self-citationWung, J. K., Perry, G. L., Kowalski, A. J., Harris, P. L. R., Bishop, G. M., Trivedi, M. A., Johnson, S. C., Smith, M. A., Denhardt, D. T., & Atwood, C. (2007) · Current Alzheimer Research · doi:10.2174/156720507779939869 · Cited by 71 · see citing works
Mattsson, N., Blennow, K., & Zetterberg, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04944.x · Cited by 68 · see citing works
Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis.
Braitch, M., Nunan, R., Niepel, G., Edwards, L., & Constantinescu, C. (2008) · Archives of Neurology · doi:10.1001/archneur.65.5.633 · Cited by 59 · see citing works
Calsyntenins Mediate TGN Exit of APP in a Kinesin‐1‐Dependent Manner
Ludwig, A., Blume, J., Diep, T., Yuan, J. X., Mateos, J. M., Leuthäuser, K., Steuble, M., Streit, P., & Sonderegger, P. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00886.x · Cited by 57 · see citing works
Wang, G., Wu, W. W., Pisitkun, T., Hoffert, J. D., Knepper, M. A., & Shen, R. (2006) · Analytical Chemistry · doi:10.1021/ac060611v · Cited by 35 · see citing works
Quantification of Proteins and Metabolites by Mass Spectrometry Without Isotopic Labeling
Roy, S. M., & Becker, C. H. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-255-7_6 · Cited by 32 · see citing works
Improved Ranking Functions for Protein and Modification-Site Identifications
Bern, M. W., & Goldberg, D. T. (2008) · Journal of Computational Biology · doi:10.1089/cmb.2007.0119 · Cited by 28 · see citing works
Deyn, P. P. D., Hiramatsu, M., Borggreve, F., Goeman, J., D’Hooge, R., Saerens, J., & Mori, A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199803000-00004 · Cited by 25 · see citing works
Nonparametric Mass Calibration Using Hundreds of Internal Calibrants
Becker, C. H., Kumar, A. P., Jones, T., & Lin, H. (2007) · Analytical Chemistry · doi:10.1021/ac061359u · Cited by 11 · see citing works
Quantification of Proteins and Metabolites by Mass Spectrometry Without Isotopic Labeling
Roy, S. M., & Becker, C. H. (2007) · Humana Press eBooks · doi:10.1385/1-59745-255-6:87 · Cited by 1 · see citing works
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease
Stephan, A. H., Barres, B. A., & Stevens, B. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113810 · Cited by 1,113 · see citing works
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease
Bai, B., Hales, C. M., Chen, P.-C., Gozal, Y., Dammer, E. B., Fritz, J. J., Wang, X., Xia, Q., Duong, D. M., Street, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310249110 · Cited by 335 · see citing works
Biometal Dyshomeostasis and Toxic Metal Accumulations in the Development of Alzheimer’s Disease
Li, Y. H., Jiao, Q., Xu, H., Du, X., Shi, L., Jia, F., & Jiang, H. F. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00339 · Cited by 169 · see citing works
Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131 · see citing works
Recent advances in quantitative neuroproteomics
Craft, G. E., Chen, A., & Nairn, A. C. (2013) · Methods · doi:10.1016/j.ymeth.2013.04.008 · Cited by 126 · see citing works
Afamin — A pleiotropic glycoprotein involved in various disease states
Dieplinger, H., & Dieplinger, B. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.010 · Cited by 120 · see citing works
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112 · see citing works
Molecular Mechanisms of Metal Toxicity in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Zaman, S., Begum, Y., Ashraf, G. M., Bin-Jumah, M. N., BUNGAU, S. G., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02096-w · Cited by 109 · see citing works
Immunity and inflammation in neurodegenerative diseases.
Cappellano, G., Carecchio, M., Fleetwood, T., Magistrelli, L., Cantello, R. M., Dianzani, U., & Comi, C. (2013) · Europe PMC (PubMed Central) · Cited by 105 · see citing works
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106 · see citing works
The path from the choroid plexus to the subventricular zone: go with the flow!
Falcão, A. M. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00034 · Cited by 98 · see citing works
Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer’s disease
Kitamura, Y., Usami, R., Ichihara, S., Kida, H., Satoh, M., Tomimoto, H., Murata, M., & Oikawa, S. (2017) · Neurological Research · doi:10.1080/01616412.2017.1281195 · Cited by 97 · see citing works
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94 · see citing works
Gabbita, S. P., Srivastava, M. K., Eslami, P., Johnson, M. F., Kobritz, N., Tweedie, D., Greig, N. H., Zemlan, F. P., Sharma, S. P., & Harris‐White, M. E. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-99 · Cited by 93 · see citing works
Calsyntenins Function as Synaptogenic Adhesion Molecules in Concert with Neurexins
Um, J. W., Pramanik, G., Ko, J. S., Song, M., Lee, D., Kim, H., Park, K.-S., Südhof, T. C., Tabuchi, K., & Ko, J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.010 · Cited by 92 · see citing works
The balancing act of GABAergic synapse organizers
Ko, J., Choii, G., & Um, J. W. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.004 · Cited by 86 · see citing works
Exposure of metal toxicity in Alzheimer’s disease: An extensive review
Islam, F., Shohag, S., Akhter, S., Islam, M. R., Sultana, S., Mitra, S., Chandran, D., Khandaker, M. U., Ashraf, G. M., Idris, A. M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.903099 · Cited by 83 · see citing works
Begcevic, I., Brinc, D., Brown, M., Martinez-Morillo, E., Goldhardt, O., Grimmer, T., Magdolen, V., Batruch, I., & Diamandis, E. P. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.027 · Cited by 81 · see citing works
Eggert, S., Thomas, C., Kins, S., & Hermey, G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0806-x · Cited by 74 · see citing works
Neuroinflammation in Alzheimer’s disease: Pleiotropic roles for cytokines and neuronal pentraxins
Swanson, A., Wolf, T., Sitzmann, A., & Willette, A. A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.015 · Cited by 72 · see citing works
CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease
Shen, Y., Timsina, J., Heo, G., Beric, A., Ali, M., Wang, C., Yang, C., Wang, Y., Western, D., Liu, M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.049 · Cited by 72 · see citing works
Self-citationHendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68 · see citing works
Paterson, R., Heywood, W., Heslegrave, A., Magdalinou, N., Andreasson, U., Sirka, E., Bliss, E., Slattery, C., Toombs, J., Svensson, J., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.194 · Cited by 65 · see citing works
The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease
Iulita, M. F., & Cuello, A. C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100030 · Cited by 67 · see citing works
Novel <scp>CSF</scp> biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65 · see citing works
A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease
Pedrero-Prieto, C. M., García‐Carpintero, S., Frontiñán-Rubio, J., Llanos-González, E., García, C. A., Alcain, F. J., Lindberg, I., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09276-9 · Cited by 61 · see citing works
Quantitative proteomic analysis of the frontal cortex in Alzheimer’s disease
Sathe, G. J., Albert, M., Darrow, J. A., Saito, A., Troncoso, J. C., Pandey, A., & Moghekar, A. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15116 · Cited by 65 · see citing works
Hanzel, C. E., Iulita, M. F., Eyjolfsdottir, H., Hjorth, E., Schultzberg, M., Eriksdotter, M., & Cuello, A. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132282 · Cited by 64 · see citing works
Elevated Osteopontin Levels in Mild Cognitive Impairment and Alzheimer's Disease
Sun, Y., Yin, X.-S., Guo, H., Han, R.-K., He, R.-D., & Chi, L. (2013) · Mediators of Inflammation · doi:10.1155/2013/615745 · Cited by 63 · see citing works
CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
van der Ende, E. L., Veld, S. G. J. G. I. ‘., Hanskamp, I., van der Lee, S. J., Dijkstra, J. I. R., Hok‐A‐Hin, Y. S., Blujdea, E. R., Swieten, J. C. V., Irwin, D. J., Chen‐Plotkin, A. S., et al. (2023) · Brain · doi:10.1093/brain/awad213 · Cited by 55 · see citing works
Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids
Wu, C., Duan, J., Liu, T., Smith, R. D., & Qian, W. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.01.015 · Cited by 59 · see citing works
Nagase, T., & Tohda, C. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12830 · Cited by 56 · see citing works
Plasma Signaling Proteins in Persons at Genetic Risk for Alzheimer Disease
Ringman, J. M., Elashoff, D. A., Geschwind, D. H., Welsh, B. T., Gylys, K. H., Lee, C., Cummings, J. L., & Cole, G. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.277 · Cited by 55 · see citing works
Self-citationPonomareva, O. Y., Holmen, I. C., Sperry, A. J., Eliceiri, K. W., & Halloran, M. C. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0561-14.2014 · Cited by 55 · see citing works
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55 · see citing works
Aulston, B. D., Liu, Q., Mante, M., Florio, J. B., Rissman, R. A., & Yuan, S. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190656 · Cited by 54 · see citing works
Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martinez-Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Gkioka, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.15095.1 · Cited by 51 · see citing works
Llano, D. A., Bundela, S., Mudar, R. A., Devanarayan, V., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182098 · Cited by 51 · see citing works
Ghosal, K., Stathopoulos, A. M., Thomas, D. G., Phenis, D., Vitek, M. P., & Pimplikar, S. W. (2012) · Neurodegenerative Diseases · doi:10.1159/000341299 · Cited by 50 · see citing works
Mass spectrometry-based proteomics and peptidomics for systems biology and biomarker discovery
Cunningham, R., Ma, D., & Li, L. (2012) · Frontiers in Biology · doi:10.1007/s11515-012-1218-y · Cited by 46 · see citing works
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 46 · see citing works
Explorative and targeted neuroproteomics in Alzheimer's disease
Brinkmalm, A., Portelius, E., Öhrfelt, A., Brinkmalm, G., Andréasson, U., Gobom, J., Blennow, K., & Zetterberg, H. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.01.009 · Cited by 45 · see citing works
Muenchhoff, J., Poljak, A., Thalamuthu, A., Gupta, V. B., Chatterjee, P., Raftery, M. J., Masters, C. L., Morris, J. C., Bateman, R. J., Fagan, A. M., et al. (2016) · Scientific Reports · doi:10.1038/srep29078 · Cited by 45 · see citing works
Bastos, P. A. D., Ferreira, R. M., Manadas, B. J., Moreira, P. I., & Vitorino, R. M. P. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1299682 · Cited by 40 · see citing works
Use of proteomic methods in the analysis of human body fluids in A lzheimer research
Zürbig, P., & Jahn, H. (2012) · Electrophoresis · doi:10.1002/elps.201200360 · Cited by 37 · see citing works
Amyloid β and free heme: bloody new insights into the pathogenesis of Alzheimer’s disease
Flemmig, J., Zámocký, M., & Alia, A. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.235021 · Cited by 38 · see citing works
van der Ende, E. L., Heller, C., Sogorb‐Esteve, A., Swift, I. J., McFall, D. J., Peakman, G., Bouzigues, A., Poos, J. M., Jiskoot, L. C., Panman, J. L., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02573-0 · Cited by 37 · see citing works
A new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 34 · see citing works
Kim, D.-K., Park, J., & Choi, B. (2014) · The Journal of Toxicological Sciences · doi:10.2131/jts.39.625 · Cited by 37 · see citing works
Mehta, S. R., Pérez‐Santiago, J., Hulgan, T., Day, T. R. C., Barnholtz‐Sloan, J. S., Gittleman, H. R., Letendre, S. L., Ellis, R. J., Heaton, R. K., Patton, S. M., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0848-z · Cited by 35 · see citing works
Ehtewish, H., Mesleh, A. G., Ponirakis, G., de la Fuente, A., Parray, A., Bensmail, I., Abdesselem, H., Ramadan, M., Khan, S., Chandran, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098117 · Cited by 36 · see citing works
Free Heme and Amyloid-β: A Fatal Liaison in Alzheimer’s Disease
Chiziane, E., Telemann, H., Krueger, M. C., Adler, J., Arnhold, J., Alia, A., & Flemmig, J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170711 · Cited by 33 · see citing works
Connor, D. E., Chaitanya, G. V., Chittiboina, P., McCarthy, P., Scott, L. K., Schrott, L. M., Minagar, A., Nanda, A., & Alexander, J. S. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.04.003 · Cited by 32 · see citing works
Systematic Review: microRNAs as Potential Biomarkers in Mild Cognitive Impairment Diagnosis
Ogonowski, N. S., Salcidua, S., León, T., Chamorro-Veloso, N., Valls, C., Avalos, C., Bisquertt, A., Rentería, M. E., Orellana, P., & Duran-Aniotz, C. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.807764 · Cited by 32 · see citing works
Mitochondrial Targeting in Neurodegeneration: A Heme Perspective
Fiorito, V., Chiabrando, D., & Tolosano, E. (2018) · Pharmaceuticals · doi:10.3390/ph11030087 · Cited by 30 · see citing works
F-spondin gene transfer improves memory performance and reduces amyloid-β levels in mice
Hafez, D. M., Huang, J., Richardson, J. C., Masliah, E., Peterson, D. A., & Marr, R. A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.038 · Cited by 29 · see citing works
Lee, T. J., Lee, J. W., Haynes, E. M., Eliceiri, K. W., & Halloran, M. C. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00107 · Cited by 29 · see citing works
Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer’s Disease
Robinson, R. A. S., Amin, B., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_2 · Cited by 28 · see citing works
Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update
Portelius, E., Brinkmalm, G., Pannee, J., Zetterberg, H., Blennow, K., Dahlén, R., Brinkmalm, A., & Gobom, J. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1384697 · Cited by 26 · see citing works
A systems biology approach for studying neurodegenerative diseases
Lam, S. C. C., Bayraktar, A., Zhang, C., Türkez, H., Nielsen, J., Borén, J., Shoaie, S., Uhlén, M., & Mardinoğlu, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.05.010 · Cited by 24 · see citing works
Afamin promotes glucose metabolism in papillary thyroid carcinoma
Shen, C., Wei, W., Qiu, Z., Song, H.-J., & Luo, Q. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.013 · Cited by 24 · see citing works
Proteome alterations in aqueous humour of primary open angle glaucoma patients
Liu, H. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2020.01.24 · Cited by 24 · see citing works
Gupta, M. K., Jayaram, S., Madugundu, A. K., Chavan, S., Advani, J., Pandey, A., Thongboonkerd, V., & Sirdeshmukh, R. (2014) · Journal of Proteome Research · doi:10.1021/pr500023p · Cited by 22 · see citing works
Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
Rostgaard, N., Waldemar, G., Nielsen, J. E., & Simonsen, A. H. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000381828 · Cited by 22 · see citing works
Recent developments in proteomic methods and disease biomarkers
Bergman, N. P., & Bergquist, J. (2014) · The Analyst · doi:10.1039/c4an00627e · Cited by 21 · see citing works
VanDusen, K. W., Li, Y., Cai, V., Hall, A., Hiles, S., Thompson, J. W., Moseley, M. A., Cooter, M. L., Acker, L., Levy, J. H., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201544 · Cited by 21 · see citing works
Translational proteomics in Alzheimer's disease and related disorders
Ghidoni, R., Paterlini, A., & Benussi, L. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.10.012 · Cited by 21 · see citing works
Plasma Biomarkers: Potent Screeners of Alzheimer’s Disease
Naveed, M., Mubeen, S., Khan, A., Ibrahim, S., & Meer, B. (2019) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519848239 · Cited by 21 · see citing works
Osteopontin: A novel marker of pre‐symptomatic sporadic Alzheimer's disease
Quesnel, M. J., Labonté, A., Picard, C., Bowie, D. C., Zetterberg, H., Blennow, K., Brinkmalm, A., Villeneuve, S., Poirier, J., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14065 · Cited by 20 · see citing works
Hamid, A. R., & Tran, Q. N. (2015) · Cited by 20 · see citing works
AMPA receptors in Alzheimer disease: Pathological changes and potential therapeutic targets
Ning, L., Shen, R., Xie, B., Jiang, Y., Geng, X., & Dong, W. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae093 · Cited by 19 · see citing works
New Insight into Neurodegeneration: the Role of Proteomics
Pal, R., Alves, G. W., Larsen, J. P., & Møller, S. G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8590-8 · Cited by 19 · see citing works
Navas-Carrillo, D., Rivera‐Caravaca, J. M., Sampedro-Andrada, A., & Orenes‐Piñero, E. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1833298 · Cited by 19 · see citing works
Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ
Matafora, V., Gorb, A., Yang, F., Noble, W. J., Bachi, A., Perez‐Nievas, B. G., & Jiménez-Sánchez, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15875 · Cited by 18 · see citing works
Devanarayan, P., Devanarayan, V., Llano, D. A., & (ADNI), T. A. D. N. I. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180905 · Cited by 18 · see citing works
Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
Galasko, D. R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00256 · Cited by 18 · see citing works
van Zalm, P., Ahmed, S., Fatou, B., Schreiber, R., Barnaby, O. S., Boxer, A. L., Zetterberg, H., Steen, J. A. J., & Steen, H. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101005 · Cited by 17 · see citing works
The Potential of Proteomics in Understanding Neurodegeneration
Pal, R., Larsen, J. P., & Møller, S. G. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.002 · Cited by 17 · see citing works
Calsyntenins Are Expressed in a Dynamic and Partially Overlapping Manner during Neural Development
Francàs, G. D. R., Alther, T. A., & Stoeckli, E. T. (2017) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2017.00076 · Cited by 15 · see citing works
Progress in Alzheimer’s disease research in the last year
Galimberti, D., & Scarpini, E. A. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6921-3 · Cited by 14 · see citing works
Patel, S. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.25 · Cited by 13 · see citing works
Proteomics and Neurodegenerative Disorders: Advancements in the Diagnostic Analysis
Puranik, N., Yadav, D., Yadav, S. K., Chavda, V. K., & Jin, J. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721666200511094222 · Cited by 12 · see citing works
Neural regulation of energy and bone homeostasis by the synaptic adhesion molecule Calsyntenin-3
Kim, S., Jeong, Y. T., Jeong, S. R., Park, M., Go, H. S., Kim, M. Y., Seong, J. K., Kim, K. W., Seo, J. T., Kim, C. H., et al. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0419-8 · Cited by 11 · see citing works
Li, N., Cao, S., Yu, Z., Qiao, M., Cheng, Y., Shen, Y., Song, L., Huang, X., Yang, G., & Zhao, Y. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02241-5 · Cited by 11 · see citing works
Shi, L., Buchanan, C. R., Cox, S. R., Hillary, R. F., Marioni, R. E., Campbell, A. I., Hayward, C., Stolicyn, A., Whalley, H. C., Harris, M. A., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12240 · Cited by 11 · see citing works
Pedrero-Prieto, C. M., Frontiñán-Rubio, J., Alcain, F. J., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11091655 · Cited by 12 · see citing works
Safi, A., Giunti, E., Melikechi, O., Xia, W., & Melikechi, N. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42349 · Cited by 10 · see citing works
Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer’s Disease
Shen, L., Xia, S., Zhang, H., Yao, F., Liu, X., Zhao, Y., Ying, M., Iqbal, J., & Liu, Q. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82035 · Cited by 10 · see citing works
PSEN1 c.1292C<A Variant and Early-Onset Alzheimer’s Disease: A Scoping Review
Orozco-Barajas, M., Oropeza-Ruvalcaba, Y., Canales-Aguirre, A. A., & Sánchez-González, V. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.860529 · Cited by 10 · see citing works
Recent Advances in Proteomics Research
Magdeldin, S. (2015) · InTech eBooks · doi:10.5772/59739 · Cited by 10 · see citing works
Shen, Y., Ali, M., Timsina, J., Wang, C., Do, A. N., Western, D., Liu, M., Gorijala, P., Budde, J., Liu, H., et al. (2024) · medRxiv · doi:10.1101/2024.01.12.24301242 · Cited by 10 · see citing works
Self-citationFaldu, K. G., & Shah, J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2104639 · Cited by 9 · see citing works
Abbasi, D. A., Nguyen, T. T. A., Hall, D. A., Robertson-Dick, E. E., Berry‐Kravis, E., & Cologna, S. M. (2021) · The Cerebellum · doi:10.1007/s12311-021-01262-7 · Cited by 8 · see citing works
Anderson, C. L., Gross, A. L., Pettigrew, C. A., Vazquez, J. P., Moghekar, A., Oh, S., Na, C. H., Albert, M., Worley, P. F., & Soldan, A. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.09.002 · Cited by 7 · see citing works
Bilousova, T. V., Taylor, K. M., Emirzian, A., Gylys, R., Frautschy, S. A., Cole, G. M., & Teng, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.006 · Cited by 7 · see citing works
When Does Alzheimer’s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-Á., Cervera‐Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19305 · Cited by 7 · see citing works
Neuroproteomics — LC-MS Quantitative Approaches
Santa, C., Anjo, S. I., Mendes, V. M., & Manadas, B. J. (2015) · InTech eBooks · doi:10.5772/61298 · Cited by 7 · see citing works
Changes of Cerebrospinal Fluid Peptides due to Tauopathy
Majerová, P., Baráth, P., Michalicová, A., Katina, S., Novák, M., & Kováč, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170110 · Cited by 7 · see citing works
- Authors
- Ringman, J. M.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Ringman, John M.
- ORCID
- Ringman, John M.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-01-01
- Volume
- 69
- Issue
- 1
- Pages
- 96
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC3632731
- OpenAlex
- W2153569004
- Cited by
- 124
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 10 · 2019: 8 · 2018: 11 · 2017: 12 · 2016: 7 · 2015: 13 · 2014: 11 · 2013: 6 · 2012: 14
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (7rc2ns069502-02, UL1TR000124)
- National Institute on Aging (K08 AG-22228, K08AG022228, P50AG016570, P50-AG 16570)
- National Institute of Neurological Disorders and Stroke (RC2 NS069502, 5RC2NS069502)
- National Center for Research Resources ((M01 RR00865), M01RR000865)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- familial Alzheimer's disease, cerebrospinal fluid proteome, presymptomatic biomarkers, PSEN1 mutations, APP mutations, presenilin 1, amyloid precursor protein, late-onset Alzheimer's disease, inflammation, synaptic loss, AMPA receptors, osteopontin, neurodegeneration
- MeSH terms
- Adult, Alzheimer Disease, Cerebrospinal Fluid Proteins, Chromatography, Liquid, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Models, Biological, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Statistics, Nonparametric, Proteomics, Tandem Mass Spectrometry, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
